Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday ...

The FDA has cleared Iterum’s oral antibiotic for certain patients with uncomplicated urinary tract infections (uUTIs) who ...

Bristol Myers Squibb and Ideaya Biosciences both released detailed snapshots of early-stage data for cancer drugs targeting ...

On the heels of her reelection in July, European Commission President Ursula von der Leyen tasked her new ...

A group of four Republicans on the House Committee on Energy and Commerce called for more transparency of clinical trial data ...

The future of Telix Pharmaceuticals' new spinout Rhine Pharma hinges on the outcome of one early-stage trial, Telix CEO ...

GSK said it is making its largest manufacturing investment in the US yet, allocating $800 million to upgrade its vaccine ...

Elucida Oncology, a clinical-stage biotech led by former Pfizer executive Geno Germano, has shut down, Endpoints News has ...

This week, Roche joined Eli Lilly in coming out against a deal that would add significant new manufacturing capacity to Novo ...

Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on ...

Tyra Biosciences unveiled early trial results on its FGFR3-specific inhibitor in advanced bladder cancer patients on Friday, the public company’s first presentation of human data since ...

Plus, news about Tectonic Therapeutic, Molecular Partners and Arcus Biosciences: EnGene snags $60M: The Boston and Montreal gene therapy biotech raised the private placement from new ...